ClinicalTrials.gg
CompletedNCT01495910Updated Feb 28, 2014

A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency

A Phase 1 interventional study of Abiraterone acetate in 21-hydroxylase Deficiency, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed at 3 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-28.

Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of this study is to determine the minimum dose of abiraterone acetate needed to decrease serum androstenedione to age-appropriate levels in premenopausal women on steroid replacement for classic 21-hydroxylase deficiency.

Read the detailed description

This is a non-randomized (patients will not be assigned by chance to study treatments), open-label (patients will know the identity of study treatments), multiple-dose, intra-patient sequential dose-escalation study with a planned enrollment of approximately 10 patients. This study will consist of a screening period and a treatment period. Due to the intra-patient dose escalation, there will be multiple treatment periods consisting of 8 days each. A rest period of at least 7 days will separate each treatment period. Eligible patients will take study-defined replacement doses of hydrocortisone and fludrocortisone. Abiraterone acetate oral suspension will be administered in daily escalating doses from 100 mg to 500 mg. Patients will proceed to the next higher dose level when the majority of the treated patients have a reduction in the androstenedione level. Serial pharmacokinetic (study of what the body does to a drug) and pharmacodynamic (study of the effects of a drug on the body) samples will be collected at each treatment period as detailed in the protocol. All patients who receive at least 1 dose of abiraterone acetate will be analyzed for safety.

02

Conditions studied

  • 21-hydroxylase Deficiency

Keywords

  • 21-hydroxylase deficiency
  • Androstenedione
  • Abiraterone acetate
  • Pharmacokinetics
  • Pharmacodynamics
  • Dose-finding
03

In context

Lead sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the lead sponsor of 465 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Premenopausal women >=18 years of age.
  • Must be receiving a hormonal agent containing both estrogen and progesterone.
  • Confirmed 21-hydroxylase deficiency by CYP21A2 genotype associated with classic congenital adrenal hyperplasia.
  • Demonstrates a >=1.5 X of morning serum androstenedione concentration while taking study-defined doses of hydrocortisone and fludrocortisone.
  • No coexisting medical conditions in the opinion of the investigator that would preclude participation in the study.

Exclusion criteria

Exclusion Criteria:

  • Current or history of active or chronic hepatitis, including symptomatic viral hepatitis A, B, or C.
  • Any active infection.
  • Evidence of active .
  • Serious or uncontrolled co-existent non-malignant disease.
  • Receiving systemic for any reason other than for the treatment of 21-hydroxylase deficiency.
  • Any disorders that require treatment with anticonvulsants.
  • Patients of who are not willing to use a method of during the study and for 3 months after the end-of-study.
  • Women who are pregnant or breast-feeding.
  • Genotypes associated with non-classic congenital adrenal hyperplasia.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Abiraterone acetate

    Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.

    Drug: Abiraterone acetate

Interventions

  • Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.

06

What researchers measure

Primary outcomes

  1. The minimum dose of abiraterone acetate required to decrease serum androstenedione to the age-appropriate range for adult women with 21-hydroxylase deficiency

    Normalization or reduction of age-appropriate androstenedione levels will be determined by the mean of the androstenedione values measured on Study Days 6 and 7 of the treatment period.

    Time frame: Up to Day 7 of each treatment period.

Secondary outcomes

  1. Mean serum concentrations of androstenedione

    Time frame: Up to Day 8 of each treatment period.

  2. Mean serum concentrations of 17-hydroxyprogesterone

    Time frame: Up to Day 8 of each treatment period.

  3. Mean plasma concentrations of renin activity

    Time frame: Up to Day 8 of each treatment period.

  4. Mean serum concentrations of testosterone

    Time frame: Up to Day 8 of each treatment period.

  5. Urine concentrations of androsterone

    Time frame: Up to Day 8 of each treatment period.

  6. Urine concentrations of etiocholanolone

    Time frame: Up to Day 8 of each treatment period.

  7. Maximum plasma concentration (Cmax) of abiraterone

    Time frame: Up to Day 8 of each treatment period.

  8. Time to reach the maximum plasma concentration (tmax) of abiraterone

    Time frame: Up to Day 8 of each treatment period.

  9. Area under the plasma concentration-time curve from time 0 to 24 hours postdose (AUC24) of abiraterone

    Time frame: Up to Day 8 of each treatment period.

  10. Area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration (AUClast) of abiraterone

    Time frame: Up to Day 8 of each treatment period.

  11. Time to last quantifiable plasma concentration (Tlast) of abiraterone

    Time frame: Up to Day 8 of each treatment period.

  12. Elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of abiraterone

    Time frame: Up to Day 8 of each treatment period.

07

Study locations

3 sites
  • Chicago, Illinois, United States
  • Ann Arbor, Michigan, United States
  • Dallas, Texas, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2011
First posted
Dec 20, 2011
Start
Dec 2011
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Last update
Feb 28, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01495910
Responsible party
Sponsor
First posted
Dec 20, 2011
Start date
Dec 2011
Primary completion
Feb 2013
Completion
Feb 2013
Last update
Feb 28, 2014

Study contacts

Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Clinical Trial
study director · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abiraterone Acetate

Start the discussion